Summary
- Profile Type
- Technology offer
- POD Reference
- TOGB20240911015
- Term of Validity
- 11 September 2024 - 11 September 2025
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- Germany
- Sweden
- France
- Italy
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- This biotech startup is active in the Netherlands and the United Kingdom, developing cellular immunotherapies against solid tumours and ischemic diseases. The technology is a platform technology that can be incorporated into many different CAR-based cellular therapies to restrict CAR expression to the solid tumour. As such, their technology preserves the killing capacity of the cells and reduces the toxicity of these therapies. The company is looking for co-development partners developing their
- Full Description
- The biotech startup is linked to a UK Russell Group university, from which the technology was licensed. The company develops in-house cellular immunotherapy assets like CAR-T specifically against solid tumours which is a state of art approach. The technology has reached pre-clinical stage and can be licensed to other CAR manufacturers, hence the offer to enter into collaboration/co-development for additional assets that can be developed. These assets can for instance induce antifibrotic signalling in ischemic diseases, reduce organ transplantation immunity etc.
- Advantages and Innovations
-
- Superior in vivo safety, absence of lung/liver reactivity
- Higher dosing of CAR-cells possible without toxicity
- Targeting of ubiquitous antigens, no tumour heterogeneity issues, avoiding antigen escape
- Avoiding cell exhaustion, yielding fitter CAR-T products
- Suitable for allogenic and autologous approaches, any CAR or carrier cell
- Patent pending all major markets; leading patent position compared to competition - Stage of Development
- Concept stage
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR description
- The partner should either develop CAR-based cell therapies that may benefit from increased safety and increased efficacy or have IP/know how on novel CAR-based cell therapy applications and/or constructs that the partner intends to develop.
Partner Sought
- Expected Role of a Partner
- The partner should support an agreement that holds a product development roadmap with go/no-go phases and commercialisation structure. Preferred partners could include companies looking to develop cell therapy treatments including large biopharmaceutical companies with an interest in solid tumours as well as SMEs who are looking to apply CAR-T cell therapy to other conditions. These organisations could be located in Germany, Italy, France and/or Sweden.
- Type and Size of Partner
- SME 50 - 249
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001019 - Stem cell Technologies
- Market keywords
- 05003001 - Therapeutic services
- Sector Groups Involved
- Health
- Targeted countries
- Germany
- Sweden
- France
- Italy